Publications by authors named "H Chesson"
Objectives: Economic models assessing vaccinations commonly assume that inflation-adjusted vaccine costs are constant over time. This study assessed this assumption using historical vaccine cost data.
Methods: Private sector and CDC contracted vaccine cost data (2001-2023) were collected from the CDC Vaccine Price List and converted to US$2023 to adjust for inflation.
Article Synopsis
- - The study investigates the cost-effectiveness of expanding HPV vaccination to U.S. adults aged 27-45, particularly those at higher risk for HPV-related diseases, by modeling the potential outcomes over a 100-year timeframe.
- - It found that vaccinating mid-adults generally costs more per life year gained compared to vaccinating younger individuals, with varying costs and effectiveness depending on risk factors like number of sexual partners and recent relationship status.
- - The most efficient strategy identified was vaccinating women who have recently separated and have many lifetime partners, offering a lower cost per quality-adjusted life-year and fewer individuals needed to vaccinate to prevent one cancer case.
Background: We compared racial and ethnic disparities in HIV diagnosis rates among adults in census tracts with the most disadvantaged vs. the most advantaged levels of social determinants of health.
Methods: In this ecologic analysis, we used the National HIV Surveillance System data from 2021 and social determinants of health data from 2017-2021 American Community Survey.
Introduction: Disease intervention specialists (DIS) are critical for delivering partner services programs that provide partner notification, counseling, referral, and other services for HIV, sexually transmitted infections (STIs), and other infections. This systematic review of partner services and other DIS-delivered interventions for HIV and STIs was conducted to summarize the effectiveness of these programs and identify evidence gaps.
Methods: A systematic literature review was conducted with a narrative synthesis.
Background: Productivity costs of sexually transmitted infections (STIs) reflect the value of lost time due to STI morbidity and mortality, including time spent traveling to, waiting for, and receiving STI treatment. The purpose of this study was to provide updated estimates of the average lifetime productivity cost for chlamydia, gonorrhea, and syphilis, per incident infection.
Methods: We adapted published decision tree models from recent studies of the lifetime medical costs of chlamydia, gonorrhea, and syphilis in the United States.